Short Interest in Aptorum Group Limited (NASDAQ:APM) Rises By 3,995.8%

Aptorum Group Limited (NASDAQ:APM) saw a significant increase in short interest during the month of June. As of June 15th, there was short interest totaling 101,658 shares, an increase of 3,995.8% from the May 31st total of 2,482 shares. Currently, 4.4% of the shares of the company are sold short. Based on an average daily trading volume, of 583,559 shares, the short-interest ratio is presently 0.2 days.

Analyst Ratings Changes

Separately, Weiss Ratings raised Aptorum Group from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Aptorum Group has an average rating of “Sell”.

Aptorum Group Stock Down 4.5%

APM stock opened at $0.78 on Friday. The company has a 50-day simple moving average of $0.89 and a 200 day simple moving average of $0.94. Aptorum Group has a fifty-two week low of $0.65 and a fifty-two week high of $4.47.

Aptorum Group Company Profile

Aptorum Group Ltd. (NASDAQ: APM) is a global biopharmaceutical company incorporated under the laws of the Cayman Islands and headquartered in Hong Kong. Since its Nasdaq listing in 2018, the company has focused on the discovery, development and commercialization of novel therapeutics and diagnostic products. Aptorum’s research efforts are aimed at addressing unmet medical needs across oncology, metabolic disorders, infectious diseases and neurological conditions.

The company’s diversified pipeline includes both small-molecule and biologic drug candidates, as well as companion diagnostic tools.